propranolol has been researched along with Parkinsonian Disorders in 6 studies
Propranolol: A widely used non-cardioselective beta-adrenergic antagonist. Propranolol has been used for MYOCARDIAL INFARCTION; ARRHYTHMIA; ANGINA PECTORIS; HYPERTENSION; HYPERTHYROIDISM; MIGRAINE; PHEOCHROMOCYTOMA; and ANXIETY but adverse effects instigate replacement by newer drugs.
propranolol : A propanolamine that is propan-2-ol substituted by a propan-2-ylamino group at position 1 and a naphthalen-1-yloxy group at position 3.
Parkinsonian Disorders: A group of disorders which feature impaired motor control characterized by bradykinesia, MUSCLE RIGIDITY; TREMOR; and postural instability. Parkinsonian diseases are generally divided into primary parkinsonism (see PARKINSON DISEASE), secondary parkinsonism (see PARKINSON DISEASE, SECONDARY) and inherited forms. These conditions are associated with dysfunction of dopaminergic or closely related motor integration neuronal pathways in the BASAL GANGLIA.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In Parkinson's disease (PD), the long term use of L-DOPA results in major adverse effects including dyskinesia or abnormal involuntary movements." | 1.36 | The selective alpha1 adrenoceptor antagonist HEAT reduces L-DOPA-induced dyskinesia in a rat model of Parkinson's disease. ( Buck, K; Ferger, B, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Sharma, VD | 1 |
| Gupta, HV | 1 |
| Espay, AJ | 1 |
| Dietlein, M | 1 |
| Dietlein, F | 1 |
| Drzezga, A | 1 |
| Bhide, N | 1 |
| Lindenbach, D | 1 |
| Barnum, CJ | 1 |
| George, JA | 1 |
| Surrena, MA | 1 |
| Bishop, C | 1 |
| Buck, K | 1 |
| Ferger, B | 1 |
| Davies, JS | 1 |
| Morrish, PK | 1 |
| Scanlon, MF | 1 |
6 other studies available for propranolol and Parkinsonian Disorders
| Article | Year |
|---|---|
Copulatory Dyskinesia: Pathognomonic Manifestation of Tardive Dyskinesia.
Topics: Adrenergic beta-Antagonists; Aged; Aripiprazole; Clonazepam; Deprescriptions; Depressive Disorder; D | 2020 |
Topics: Adrenergic beta-Antagonists; Animals; Drug Utilization; Humans; Parkinsonian Disorders; Propranolol | 2018 |
Effects of the beta-adrenergic receptor antagonist Propranolol on dyskinesia and L-DOPA-induced striatal DA efflux in the hemi-parkinsonian rat.
Topics: Adrenergic beta-Antagonists; Animals; Antiparkinson Agents; Chromatography, High Pressure Liquid; Co | 2015 |
The selective alpha1 adrenoceptor antagonist HEAT reduces L-DOPA-induced dyskinesia in a rat model of Parkinson's disease.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; | 2010 |
Controlling essential tremor.
Topics: Diagnosis, Differential; Essential Tremor; Health Status; Humans; Middle Aged; Neurologic Examinatio | 2012 |
Graves' disease presenting as hemiparkinsonism.
Topics: Adrenergic beta-Antagonists; Adult; Antithyroid Agents; Autoantibodies; Carbimazole; Diagnosis, Diff | 2001 |